Flora Growth | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 9.748 M

LB filings
2025.11.05 22:38
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 9.748 M, missing the estimate of USD 12.52 M.

EPS: As of FY2025 Q3, the actual value is USD -9.05.

EBIT: As of FY2025 Q3, the actual value is USD -3.205 M.

Financial Metrics by Segment

Commercial & Wholesale Segment

  • Revenue: $26.3 million for the nine months ended September 30, 2025, compared to $28.2 million for the same period in 2024.
  • Cost of Sales: $24.8 million for the nine months ended September 30, 2025, compared to $26.3 million for the same period in 2024.
  • Gross Profit: $1.5 million for the nine months ended September 30, 2025, compared to $1.9 million for the same period in 2024.
  • Consulting and Management Fees: $1.1 million for the nine months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Professional Fees: $1.6 million for the nine months ended September 30, 2025, compared to $2.0 million for the same period in 2024.
  • General and Administrative Expenses: $1.1 million for the nine months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Travel Expenses: $0.1 million for both the nine months ended September 30, 2025, and the same period in 2024.
  • Share-based Compensation Expenses: $0.9 million for the nine months ended September 30, 2025, compared to $0.4 million for the same period in 2024.
  • Operating Lease Expenses: $0.1 million for both the nine months ended September 30, 2025, and the same period in 2024.
  • Depreciation and Amortization Expense: Less than $0.1 million for both the nine months ended September 30, 2025, and the same period in 2024.
  • Asset Impairment: Less than $0.1 million for both the nine months ended September 30, 2025, and the same period in 2024.
  • Gain on Disposal of Insolvent Subsidiaries: $1.1 million for the nine months ended September 30, 2025, compared to $nil for the same period in 2024.
  • Other Expenses: $1.4 million for the nine months ended September 30, 2025, compared to $0.8 million for the same period in 2024.
  • Net Income (Loss) Before Income Taxes: - $5.4 million for the nine months ended September 30, 2025, compared to - $5.5 million for the same period in 2024.
  • Income Tax Expense: $0.1 million for both the nine months ended September 30, 2025, and the same period in 2024.
  • Net Loss from Continuing Operations: - $5.5 million for the nine months ended September 30, 2025, compared to - $5.5 million for the same period in 2024.

Corporate & Eliminations Segment

  • Consulting and Management Fees: $1.7 million for the nine months ended September 30, 2025.
  • Share-based Compensation Expenses: $0.9 million for the nine months ended September 30, 2025.
  • Impairment Expense: $0.05 million for the nine months ended September 30, 2025.
  • Gain on Disposal of Insolvent Subsidiaries: - $10.5 million for the nine months ended September 30, 2025.
  • Changes in Financial Instruments Fair Value: - $0.2 million for the nine months ended September 30, 2025.
  • Interest Expense, Net: $0.06 million for the nine months ended September 30, 2025.
  • Other Segment Items: $3.0 million for the nine months ended September 30, 2025.
  • Net Income (Loss) Before Income Taxes: - $16.0 million for the nine months ended September 30, 2025.
  • Income Tax Expense: $0.1 million for the nine months ended September 30, 2025.
  • Net Loss from Continuing Operations: - $16.0 million for the nine months ended September 30, 2025.

Future Outlook and Strategy

Core Business Focus

  • The Company is focusing on its global pharmaceutical distribution business through its wholly owned subsidiary Phatebo, which operates in Germany and distributes pharmaceutical products within 28 countries globally.
  • The Company is implementing an expansion strategy focused on identifying and pursuing complementary growth opportunities within the global digital asset market.

Non-Core Business

  • The Company has disposed of its legacy hemp and cannabis business to focus on its core pharmaceutical distribution and digital asset treasury strategy.

Priority

  • The Company believes that its existing cash and digital assets are and will be sufficient in both the short and long term to meet its working capital requirements and future obligations.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.